AKT1 and diabetes mellitus: Moreover, in silico studies have confirmed thymoquinone’s strong binding affinity to microbial virulence regulators (e.g., LasR, PqsR) and human diabetes-related targets (e.g., AKT1), supporting its dual application as an antidiabetic and antimicrobial agent (36).